Prophecy Market Insights’ Post

𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬: 𝐀 𝐍𝐞𝐰 𝐄𝐫𝐚 𝐢𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 📌𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅𝐬 𝐚𝐭: https://lnkd.in/gJ9KQi43 (𝙐𝙨𝙚 𝘾𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙈𝙖𝙞𝙡 𝙄𝙙 𝙛𝙤𝙧 𝙌𝙪𝙞𝙘𝙠 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚) The fight against Alzheimer’s disease has reached a turning point with groundbreaking advancements in #Alzheimer’s #therapeutics. From targeted treatments that aim to slow disease progression to innovative #biopharmaceuticals enhancing cognitive function, the future looks promising for patients and families affected by this devastating condition. 🌟 𝐊𝐞𝐲 𝐅𝐨𝐜𝐮𝐬 𝐀𝐫𝐞𝐚𝐬: ✔️ Disease-modifying therapies for early intervention ✔️ Biomarkers for personalized treatment approaches ✔️ Ongoing research in neuroprotective strategies As we move forward, collaboration between researchers, healthcare providers, and #pharmaceutical companies is key to unlocking the full potential of Alzheimer’s therapeutics. 📌𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: I don't intend any copyright (DM me for credit & removal) #Alzheimers #Therapeutics #Biopharma #Neuroscience #HealthcareInnovation #AlzheimersAwareness #ClinicalTrials #FutureOfHealth

2023 was a horrible year for #initialpublicofferings in #biotech. However, the #IPO market continues to grow in early 2024 with two companies jumping into the fray—Alto Neuroscience and Kyverna Therapeutics. https://lnkd.in/g8BRY6ef #biotechnology #IPOnews #neuroscience #CARTcells BioSpace

🔬Harnessing Electricity: The Future of Medicine🔬 Since the 1990s, research has unveiled the dual-directional role of the vagus nerve, not only sending signals to the brain but also relaying messages back to vital organs. This discovery opened new avenues, leading to innovative treatments for conditions like epilepsy and treatment-resistant depression through nerve stimulation techniques. Now, the potential of these breakthroughs is being broadened, aiming at conditions ranging from rheumatoid arthritis to autoimmune disorders. The future of bioelectronic medicine is bright, promising a shift toward less invasive, more precise interventions that align with our body's natural systems. The convergence of neuroscience, technology, and health holds transformative potential, as we continue to innovate and adapt in the pursuit of better, more efficient therapies. Read the full story here: https://hubs.la/Q02TX6_h0 #BioelectronicMedicine #InnovationInHealthcare #Neuroscience #OptoCeutics #MedicalResearch #40HzStimulation #HealthcareInnovation

☑️ *READ ABSTRACT BELOW:* Part 1: Modern in vitro technologies for preclinical research, including organ-on-a-chip, organoids- and assembloid-based systems, have rapidly emerged as pivotal tools for elucidating disease mechanisms and assessing the efficacy of putative therapeutics. In this context, advanced in vitro models of Parkinson's Disease (PD) offer the potential to accelerate drug discovery by enabling effective platforms that recapitulate both physiological and pathological attributes of the in vivo environment. Although these systems often aim at replicating the PD-associated loss of dopaminergic (DA) neurons, only a few have modelled the degradation of dopaminergic pathways as a way to mimic the disruption of downstream regulation mechanisms that define the characteristic motor symptoms of the disease. To this end, assembloids have been successfully employed to recapitulate neuronal pathways between distinct brain regions. (...) Ozgun A, Mater Today Bio. 2024 Feb 5;25:100992. doi: 10.1016/j.mtbio.2024.100992. PMID: 38371467; PMCID: PMC10873721. #Gesundheit #Bildung #Fuehrung #Coaching #Mindset #Motivation #Gehirn #Neuroscience #Psychologie #Persoenlichkeitsentwicklung #Kindheit #KeyNoteSpeaker #Humangenetik #Biochemie #Neuroleadership #Ernaehrung #Transformation #Stress #Demografie #Gender #Age #interkulturelleKompetenz #Epigenetik #Veraenderung #EmotionaleIntelligenz #Change #Gesellschaft #Organisationsentwicklung #Philosophie #Beratung # Quantum

🔔 EXCITING NEWS! The biggest names in #spatialbiology are uniting for the first time this May to discuss everything that drug developers must navigate in #adoption, #integration and use of new spatial technologies. Learn more here: https://ter.li/3f53eo Merck Group, Genmab, AstraZeneca, Novo Nordisk, Gilead Sciences, iTeos Therapeutics, Wellcome Sanger Institute, UCL, Genmab, Adaptimmune, University Hospital Heidelberg, Muna Therapeutics,GSK and more. Themes: #integration #portfolio #transcriptomics #integration #workflows #modesofaction #neuroscience #samples #datainterpretation #rarediseases #productdevelopment #pipelineinnocations #immunesubpopulations #tissues #mxtranscriptomics #crohnsdisease #celltherapy #AI #throughput #reproducibility #standardisation

⭐️⭐️⭐️I’m thrilled to share the recent publication of our latest research in the Journal of #MedicinalChemistry. This work represents a significant leap forward in our quest to unlock new possibilities in the field of #lifesciences, particularly in the exploration of orphan G-protein coupled receptors (GPCRs). This remarkable accomplishment was made possible through the collaboration between Boehringer Ingelheim and DOMAIN Therapeutics, showcasing how scientific excellence and #teamwork can push the boundaries of GPCR complexities. GPCRs are the largest family of human proteins, which are pivotal in numerous physiological and pathological functions. Despite their vast therapeutic potential, there’s still much to explore, especially in challenging, orphan and intractable GPCRs. One such receptor, GPR88, robustly expressed in the striatum of the central nervous system, is often implicated in many behavior-linked neurological disorders. The clinical progression of novel preclinical GPR88 agonists has been hindered by poor pharmacokinetic properties. Though the collaborative efforts of Boehringer Ingelheim and Domain, our recent study has successfully navigated these obstacles introducing a game-changer, BI-9508, a brain-penetrant GPR88-receptor-agonist tool compound. This breakthrough not only opens new possibilities in CNS research but also underscores the trade-offs required to successfully target GPR88’s allosteric pocket. Huge thanks to everyone who contributed to this project, and a special thanks to the researchers at Boehringer Ingelheim for their invaluable expertise! Participating in this study, which exemplifies the quality, originality and clarity of our collective #scientificresearch, fills me with immense pride. Exciting news: this new tool compound is now made available to the scientific community free of charge via the open innovation portal of Boehringer Ingelheim: opnMe.com. This initiative will undoubtedly advance #innovation in the life sciences industry, helping us better understand the role of GPR88 and develop breakthrough treatments in #neuroscience. Visit the website opnMe.com and order BI-9508 for free. Together, we are pushing the boundaries of medicinal chemistry and bringing hope to patients experiencing therapeutic failure.⭐️⭐️⭐️ For more details, please visit the link in comments. #biothechnology #drugdevelopment

𝗧𝗵𝗲 𝗿𝗼𝗹𝗲 𝗼𝗳 𝗖𝗕𝗗 𝗶𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 🔬 Have you ever wondered about CBD’s intriguing role in ion channel modulation? Dive into the world of pre-clinical drug discovery with our latest blog series, where we unravel the intricate relationship between CBD and ion channels. 📝 Join Marc Rogers as he explores exciting research on CBD. His blog shines a light on CBD´s therapeutic promise. As current research and pharmaceutical efforts focus on this compound, understanding its effects on ion channels becomes crucial. What insights await you? 𝗡𝗲𝘂𝗿𝗼𝗻𝗮𝗹 𝗡𝗮𝗩𝟭.𝘅 𝗖𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Discover how CBD inhibits these channels, affecting neuronal function. 𝗢𝘁𝗵𝗲𝗿 𝗻𝗲𝘂𝗿𝗼𝗻𝗮𝗹 𝘃𝗼𝗹𝘁𝗮𝗴𝗲-𝗴𝗮𝘁𝗲𝗱 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Explore how CBD modulates various voltage-gated channels in the nervous system. 𝗦𝗸𝗲𝗹𝗲𝘁𝗮𝗹 𝗮𝗻𝗱 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗺𝘂𝘀𝗰𝗹𝗲 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Learn about CBD’s impact on muscle function. 𝗟𝗶𝗴𝗮𝗻𝗱-𝗴𝗮𝘁𝗲𝗱 𝗶𝗼𝗻𝗼𝘁𝗿𝗼𝗽𝗶𝗰 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Uncover how CBD influences these receptors. 𝗖𝗕𝗗 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝘀𝗶𝘁𝗲𝘀 𝗮𝗻𝗱 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀: Get insights into the molecular interactions. 📚 Learn more in the Pre-clinical Drug Discovery Blog. Read more: https://ow.ly/fg6g50RBVNL #DrugDevelopment #PreclinicalStudies #IonChannels #CBDResearch #Neuroscience #Cardiology

🧠 𝗨𝗻𝗰𝗼𝘃𝗲𝗿 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 ▶️ https://lnkd.in/dCmKUnyG In this exciting Inscopix, Inc. webinar, a special guest will unveil the newest findings from a project conducted through the Inscopix Discovery Lab, providing a real-world example of the application of Inscopix miniscope technology to further drug development. In addition, hear more from Dr. Jonathan Nassi on the cutting-edge in vivo imaging assay from the Inscopix Discovery Lab. This innovative approach incorporates miniscope imaging with active behavior to facilitate preclinical pharma studies assessing novel compounds. #depression #neuroscience #Therapeutics #miniscope

Did you catch our interview with Bruce Morimoto, Vice President of Drug Development at Alto Neuroscience? As an expert speaker for the 3rd Annual Digital Biomarkers & Clinical Measures in Neurology Summit, Bruce provides a concise overview of what he'll be bringing to the table in Boston next month. He outlines how he's seen the field of digital measures evolve over time, identifies the key milestones within the space, indicates the key challenges in the field, and provides insights into the current developments he's most excited about. Explore what Bruce had to say: https://ter.li/kovih7 Bruce will be speaking on a panel discussion surrounding "What is the Translational Potential of Digital Measures to Clinical Benefit & Outcomes?", joining an impressive speaker faculty consisting of the likes of Biogen, Takeda, DEEP Measures, Duke University, Alexion Pharmaceuticals, Inc., Eisai US, Pfizer, Johnson & Johnson, Novo Nordisk, Novartis, Mitsubishi Tanabe Pharma America, Regeneron, Cerevel Therapeutics, The Michael J. Fox Foundation for Parkinson's Research, Coalition for Aligning Science, South Shore Health, Bristol Myers Squibb, Boston University, Boehringer Ingelheim, Janssen Inc. and more! Learn more about the 3rd Digital Biomarkers & Clinical Measures in Neurology Summit: https://ter.li/2tniyi #DigitalBiomarkersSummit #DigitalBiomarkers #DigitalHealth #Neuroscience #DigitalSafety #DigitalScreening #SafetyMonitoring #PersonalizedHealthcare #ClinicalMeasures #ClinicalResearch #ClinicalTrials #DigitalHealth #DigitalEndpoints #DataScience #DigitalMeasurement #ClinicalValidation #Healthcare #Pharma #BioTech